Thomas E. Sharp III, PhD

Postdoctoral Research Fellow
Cardiovascular Center of Excellence
LSU Health New Orleans


2010   BA       Neuroscience 

                       Drew University, Madison NJ        

2017   PhD     Molecular and Cellular Physiology

                       Independence Blue Cross Cardiovascular Research


                       Temple University - Lewis Katz School of Medicine,

                       Philadelphia, PA


Research Interests

Dr. Sharp’s research interests are focused on the translation of novel therapeutics and technologies to combat cardiovascular diseases.  More specifically, moving from basic science screens through the preclinical large animal models to permit early phase I/II clinical trials.  Dr. Sharp’s interests include cardioprotection and novel strategies to inhibit remodeling after acute myocardial infarction (AMI) leading to the preservation or restoration of cardiac function in the setting of heart failure (HF). Dr. Sharp’s current work also involves the development and investigation of new techniques and novel strategies to alter co-morbidities which lead to the manifestation and progression of HF with preserved ejection fraction (HFpEF). Prior to joining the CV Center at LSUHSC, Dr. Sharp has previously investigated the therapeutic potential of a novel cell therapy, gene therapy, and various pharmacotherapies in the setting of AMI and HF.

Selected Publications


Sharp TE, Lefer DJ, Houser SR. Cardiometabolic heart failure and HFpEF. Still Chasing UnicornsJACC: Basic to Translational Science. 2019;4:422-424


Polhemus DJ, Trivedi RK, Sharp TE, Li Z, Goodchild TT, Scarborough A, de Couto G, Marbán E, Lefer DJ. Repeated cell transplantation and adjunct renal denervation in ischemic heart failure: Exploring modalities for improving cell therapy efficacy. Basic Research in Cardiology. 2019;114:9


Sharp TE, Polhemus DJ, Li Z, Spaletra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefer DJ, Goodchild TT. Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system. Journal of the American College of Cardiology. 2018;72:2609


Sharp TE, Kubo H, Berretta RM, Starosta T, Wallner M, Schena GJ, Hobby AR, Yu D, Trappanese DM, George JC, Molkentin JD, Houser SR. Protein Kinase C Inhibition with Ruboxistaurin Increases Contractility and Reduces Heart Size in a Swine Model of Heart Failure with Reduced Ejection Fraction. JACC: Basic to Translational Science. 2017;2:669-683


Sharp TE, Schena GJ, Hobby AR, Starosta T, Berretta RM, Wallner M, Borghetti G, Gross P, Yu D, Johnson J, Feldsott E, Trappanese DM, Toib A, Rabinowitz JE, George JC, Kubo H, Mohsin S, Houser SR. Cortical bone stem cell therapy preserves cardiac structure and function after myocardial infarction. Circulation Research. 2017;121:1263-1278


Knezevic T, Myers VD, Gordon J, Tilley DG, Sharp TE, 3rd, Wang J, Khalili K, Cheung JY, Feldman AM. Bag3: A new player in the heart failure paradigm. Heart Failure Reviews2015


Sharp TE, George JC. Stem cell therapy and breast cancer treatment: Review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment. Frontiers in Oncology. 2014;4


Full List of Publications – Sharp - PubMed